Ignite Creation Date:
2024-05-06 @ 4:07 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04871711
Status:
COMPLETED
Last Update Posted:
2022-11-02
First Post:
2021-04-29
Brief Title:
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema
Sponsor:
LEO Pharma
Organization:
LEO Pharma
Study Overview
Official Title:
A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mgg Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema DELTA 1
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DELTA 1
Brief Summary:
This was a 16-week study in adult participants with chronic hand eczema CHE The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch pain CHE symptoms and quality of life
The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance
The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-002960-30 | EUDRACT_NUMBER | None | None |